Menu
Back to Archived Journals » Biosimilars
Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.
Biosimilars
ISSN: 2230-245X
- View all (31)
- Volume 6, 2016 (6)
- Volume 5, 2015 (9)
- Volume 4, 2014 (4)
- Volume 3, 2013 (6)
- Volume 2, 2012 (4)
- Volume 1, 2011 (2)
Journal Articles:
- 31 records -
Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product
Mantovani M, Caruso CS, Facchini FDA, Pascon R, Cagnacci PRV, de Magalhães VD
Biosimilars 2016, 6:45-60
Published Date: 30 August 2016
Adalimumab: a review of the reference product and biosimilars
Azevedo VF, Troiano LDC, Galli NB, Kleinfelder A, Catolino NM, Martins PCU
Biosimilars 2016, 6:29-44
Published Date: 26 July 2016
"Step" versus "phase" in the clinical development of biosimilars: the correct noun holds the key to success
Ewesuedo R
Biosimilars 2016, 6:25-28
Published Date: 22 June 2016
Tools for the analysis and characterization of therapeutic protein species
Fuh MM, Steffen P, Schlüter H
Biosimilars 2016, 6:17-24
Published Date: 5 May 2016
Considerations in biosimilar insulin device development
Fry AR, Krentz AJ, Hompesch M
Biosimilars 2016, 6:9-15
Published Date: 16 February 2016
Development, safety, and efficacy of biosimilar adalimumab: the data so far
Gabbani T, Deiana S, Bagnoli S, Annese V
Biosimilars 2016, 6:1-7
Published Date: 29 January 2016
Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen®: a double-blind, single-dose, two-period crossover trial
Niazi SK
Biosimilars 2015, 5:93-101
Published Date: 3 November 2015
Label-free interaction analysis as a tool to demonstrate biosimilarity of therapeutic monoclonal antibodies
Sinha-Datta U, Khan S, Wadgaonkar D
Biosimilars 2015, 5:83-91
Published Date: 16 September 2015
Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study
Cuevas C, Deisenhammer F, You X, Scolnik M, Buffels R, Sperling B, Flores-Ramírez F, Macías-Islas M, Sauri-Suárez S
Biosimilars 2015, 5:75-81
Published Date: 15 September 2015
Clinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta
Mikhail A, Brown C
Biosimilars 2015, 5:65-73
Published Date: 9 September 2015
Clinical trials in the development of biosimilars: future considerations
Huneycutt BJ, Gillespie E, Woollett GR
Biosimilars 2015, 5:49-63
Published Date: 9 July 2015
Establishing a new marketplace for biologic therapy with biosimilar agents: importance of extrapolation of data
Bressler B, Dingermann T
Biosimilars 2015, 5:41-48
Published Date: 1 June 2015
Challenging issues in assessing analytical similarity in biosimilar studies
Chow SC
Biosimilars 2015, 5:33-39
Published Date: 22 May 2015
Global regulatory landscape of biosimilars: emerging and established market perspectives
Krishnan A, Mody R, Malhotra H
Biosimilars 2015, 5:19-32
Published Date: 17 February 2015
Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197
Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK, Kalita P, Patel M, Mendiratta SK
Biosimilars 2015, 5:1-18
Published Date: 31 December 2014
Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems
Kuhlmann MK, Schmidt A
Biosimilars 2014, 4:45-58
Published Date: 10 November 2014
Multidisciplinary approach to evaluating immunogenicity of biosimilars: lessons learnt and open questions based on 10 years' experience of the European Union regulatory pathway
Chamberlain PD
Biosimilars 2014, 4:23-43
Published Date: 25 June 2014
Production and analysis of a biosimilar erythropoietin in Egypt
Ebied WM, Ahmed HM, Elbarbry FA
Biosimilars 2014, 4:11-22
Published Date: 10 May 2014
Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor
Tharmarajah S, Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2014, 4:1-9
Published Date: 12 March 2014
Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:55-62
Published Date: 27 August 2013
Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia
Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2013, 3:45-53
Published Date: 27 August 2013
Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:35-43
Published Date: 21 August 2013
Current and future biosimilars: potential practical applications in rheumatology
Noaiseh G, Moreland L
Biosimilars 2013, 3:27-33
Published Date: 1 August 2013
Rituximab and biosimilars – equivalence and reciprocity
Qureshi ZP, Magwood JS, Singh S, Bennett CL
Biosimilars 2013, 3:19-25
Published Date: 14 June 2013
Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases
Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM
Biosimilars 2013, 3:1-17
Published Date: 4 January 2013
A European perspective on the market accessibility of biosimilars
Declerck PJ, Simoens S
Biosimilars 2012, 2:33-40
Published Date: 16 November 2012
The development and introduction of biosimilar anticoagulants – focus on enoxaparin
Ginsberg JS
Biosimilars 2012, 2:27-31
Published Date: 13 September 2012
Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia
Abraham I, MacDonald K
Biosimilars 2012, 2:13-25
Published Date: 6 September 2012
Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia
Waller CF
Biosimilars 2012, 2:1-11
Published Date: 20 August 2012
Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics
Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E
Biosimilars 2011, 1:13-26
Published Date: 16 June 2011
Biosimilars: an overview
Bhupinder Singh Sekhon, Vikrant Saluja
Biosimilars 2011, 1:1-11
Published Date: 15 March 2011